Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.

doi:10.1016/j.jtho.2024.07.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2024

Parikh Kaushal, Dimou Anastasios, Leventakos Konstantinos, Mansfield Aaron S, Shanshal Mohamed, Wan Yin, Lin Huamao M, Vincent Sylvie, Elliott Jennifer, Bonta Ioana R

Abstract excerpt

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) are first-line treatment options for ALK-positive (ALK+) NSCLC. Factors such as variant allele frequencies (VAFs), EML4-ALK fusion variant, and concurrent TP53 mutations (TP53mt) in circulating tumor DNA (ctDNA) may affect treatment outcomes. We evaluated their effects on time to discontinuation (TTD) of first-line treatment with next-generation ALK TKIs in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 39019326
DOI: 10.1016/j.jtho.2024.07.009

Genes

ALK
EML4
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.PMID 39019326Read ↗

Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study.Semantic proximity Read ↗

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.Semantic proximity Read ↗

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversitySemantic proximity Read ↗

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Semantic proximity Read ↗

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.Semantic proximity Read ↗

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.Semantic proximity Read ↗

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.Semantic proximity Read ↗

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.Semantic proximity Read ↗

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patientsSemantic proximity Read ↗

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.Semantic proximity Read ↗

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.